Clinical Trial Update: Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of Enfortumab Vedotin and Pembrolizumab in patients with urothelial carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Padcev (enfortumab vedotin)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Urothelial Carcinoma | Phase 2 | Status: RECRUITING